This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...

The pharma will spend up to $2.5 billion to acquire an experimental PI3K inhibitor from Scorpion, which will spin out a new ...

Following last month’s fatal shooting of an insurance executive, healthcare’s largest investor meeting has assumed a higher ...

Eli Lilly plans to acquire Scorpion's PI3Kα program for $2.5 billion, reinvesting Mounjaro and Zepbound profits to expand its precision medicines pipeline.

Fresh from a $400 million series A round, Kailera Therapeutics has shown off phase 2 data on an obesity candidate it believes ...

Czech National Bank boosted its holdings in Eli Lilly and Company (NYSE:LLY – Free Report) by 6.3% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange ...

Eli Lilly and Company (LLY) is a global leader in healthcare innovation, specializing in discovering, developing, and ...

Eli Lilly said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the ...

A new review highlights the future of anti-obesity medications that could outperform today's already blockbuster drugs like ...

Next-gen obesity biotech Metsera has filed to debut on the public markets, proposing an IPO nine months after emerging. | ...

Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a ...

The firm said it struck a three-year licensing deal with a top pharmaceutical company that will use the data to advance GLP-1 receptor agonist research.